• Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, Okajima F, Dobashi K, Mori M. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem. Biophys. Res. Commun. 367: 509-515 (2008). *

• Ariel A, Fredman G, Sun YP, Kantarci A, Van Dyke TE, Luster AD, Serhan CN. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7: 1209-1216 (2006). *

• Ariel A, Serhan CN. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol. 28: 176-183 (2007). *

• Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201: 713-722 (2005). *

• Arita M, Clish CB, Serhan CN. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem. Biophys. Res. Commun. 338: 149-157 (2005). *

• Arita M, Oh S, Chonan T, Hong S, Elangovan S, Sun YP, Uddin J, Petasis NA, Serhan CN. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281: 22847-22854 (2006). *

• Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178: 3912-3917 (2007). *

• Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U.S.A. 102: 7671-7676 (2005). *

• Bannenberg G, Arita M, Serhan CN. Endogenous receptor agonists: resolving inflammation. ScientificWorldJournal 7: 1440-1462 (2007). *

• Bannenberg GL. Resolvins: current understanding and future potential in the control of inflammation. Curr. Opin. Drug Discov. Devel. 12: 644-658 (2009).

• Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174: 4345-4355 (2005). *

• Bonventre JV. Pathophysiology of acute kidney injury: roles of potential inhibitors of inflammation. Contrib. Nephrol. 156: 39-46 (2007).

• Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 77: 327-335 (2007). *

• Calder PC. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83: 1505S-1519S (2006). *

• Calder PC. Fatty acids and immune function: relevance to inflammatory bowel diseases. Int. Rev. Immunol. 28: 506-534 (2009).

• Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot. Essent. Fatty Acids 79: 101-108 (2008). *

• Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie. 91: 791-795 (2009).

• Calder PC. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease'. PUFA, inflammatory processes and rheumatoid arthritis. Proc. Nutr. Soc. 67: 409-418 (2008). *

• Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie Feb 3 [Epub ahead of print] (2009).

• Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN, Colgan SP. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 21: 3162-3170 (2007). *

• Cawood AL, Carroll MP, Wootton SA, Calder PC. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr. Opin. Clin. Nutr. Metab. Care 8: 153-159 (2005).

• Chiang N, Serhan CN. Cell-cell interaction in the transcellular biosynthesis of novel omega-3-derived lipid mediators. Methods Mol. Biol. 341: 227-250 (2006).

• Connor KM, Sangiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N, Serhan CN, Smith LE. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13: 868-873 (2007). *

• Dangi B, Obeng M, Nauroth JM, Chung G, Bailey-Hall E, Hallenbeck T, Arterburn LM. Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6). Biochem. Pharmacol. 79: 251-260 (2010). *

• Dangi B, Obeng M, Nauroth JM, Teymourlouei M, Needham M, Raman K, Arterburn LM. Biogenic synthesis, purification and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J. Biol. Chem. 284: 14744-14759 (2009). *

• Das UN. Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease? Lipids Health Dis. 7: 19 (2008). *

• Das UN. Biological significance of essential fatty acids. J. Assoc. Physicians India 54: 309-319 (2006).

• Das UN. Essential fatty acids - a review. Curr. Pharm. Biotechnol. 7: 467-482 (2006).

• Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol. J. 1: 420-439 (2006). *

• Das UN. A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 76: 251-268 (2007). *

• Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 7: 37 (2008). *

• Das UN. Can essential fatty acids reduce the burden of disease(s)? Lipids Health Dis. 7: 9 (2008). *

• Das UN. Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids? J. Assoc. Physicians India 53: 623-627 (2005).

• Das UN. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease - but how and why? Prostaglandins Leukot. Essent. Fatty Acids 78: 11-19 (2008). *

• Das UN. Albumin and lipid enriched albumin for the critically ill. J. Assoc. Physicians India 57: 53-59 (2009).

• Das UN. COX-2 inhibitors and metabolism of essential fatty acids. Med. Sci. Monit. 11: RA233-RA237 (2005). *

• Das UN, Puskas LG. Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders. Lipids Health Dis. 8: 61 (2009). *

• Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, Cheng G, von Andrian UH, Serhan CN. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112: 848-855 (2008). *

• Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, Bonventre JV. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177: 5902-5911 (2006). *

• Farooqui AA. Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist 15: 392-407 (2009).

• Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J. Neurochem. 101: 577-599 (2007).

• Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: the battle of the Titans. Brain Res. Rev. 56: 443-471 (2007).

• Flower RJ, Perretti M. Controlling inflammation: a fat chance? J. Exp. Med. 201: 671-674 (2005). *

• Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI, Kogner P. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J. Nov 12 [Epub ahead of print] (2009). *

• Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martinez-Clemente M, Lopez-Parra M, Arroyo V, Claria J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 23: 1946-1957 (2009). *

• Haas-Stapleton EJ, Lu Y, Hong S, Arita M, Favoreto S, Nigam S, Serhan CN, Agabian N. Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS ONE 2: e1316 (2007). *

• Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179: 7021-7029 (2007). *

• Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J. 20: 401-403 (2006). *

• Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A(4) to promote the resolution of allergic airway inflammation. Nat. Immunol. 9: 873-879 (2008). *

• Herrera BS, Ohira T, Gao L, Omori K, Yang R, Zhu M, Muscara MN, Serhan CN, Van Dyke TE, Gyurko R. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br. J. Pharmacol. 155: 1214-1223 (2008). *

• Hisada T, Ishizuka T, Aoki H, Mori M. Resolvin E1 as a novel agent for the treatment of asthma. Expert Opin. Ther. Targets 13: 513-522 (2009).

• Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278: 14677-14687 (2003). *

• Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN. Resolvin E1 metabolome in local inactivation during inflammation-resolution. J. Immunol. 180: 3512-3519 (2008). *

• Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. U.S.A. 103: 11276-11281 (2006). *

• Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention. MedGenMed. 7: 18 (2005). *

• Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, Azuma T. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 16: 87-95 (2010). *

• Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr. Mol. Med. 9: 565-579 (2009).

• Jin Y, Arita M, Zhang Q, Saban DR, Chauhan SK, Chiang N, Serhan CN, Dana R. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest. Ophthalmol. Vis. Sci. 50: 4743-4752 (2009). *

• Kaarniranta K, Salminen A. NF-kappaB signaling as a putative target for omega-3 metabolites in the prevention of age-related macular degeneration (AMD). Exp. Gerontol. 44: 685-688 (2009).

• Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell. Biochem. 49: 133-143 (2008).

• Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, Toner M, Serhan CN. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181: 8677-8687 (2008). *

• Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol. 158 (Themed Section: Mediators and Receptors in the Resolution of Inflammation: Guest Editor: AG Stewart): 960-971 (2009). *

• Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. U.S.A. Jan 4 [Epub ahead of print] (2010). *

• Lu Y, Hong S, Gotlinger K, Serhan CN. Lipid mediator informatics and proteomics in inflammation resolution. ScientificWorldJournal 6: 589-614 (2006). *

• Lu Y, Hong S, Yang R, Uddin J, Gotlinger KH, Petasis NA, Serhan CN. Identification of endogenous resolvin E1 and other lipid mediators derived from eicosapentaenoic acid via electrospray low-energy tandem mass spectrometry: spectra and fragmentation mechanisms. Rapid Commun. Mass Spectrom. 21: 7-22 (2006). *

• Maillard MH. Resolvins: new derivates of fatty acids, polyunsaturated (omega-3) with therapeutic potential in inflammatory intestinal diseases. Rev. Med. Suisse. 2: 2634-2635 (2006).

• Marcheselli VL, Mukherjee PK, Arita M, Hong S, Antony R, Sheets K, Winkler JW, Petasis NA, Serhan CN, Bazan NG. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fatty Acids Nov 18 [Epub ahead of print] (2009). *

• Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A. Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22: 75-83 (2007). *

• Massaro M, Scoditti E, Carluccio MA, De Caterina R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot. Essent. Fatty Acids 79: 109-115 (2008). *

• Mayer K, Seeger W. Fish oil in critical illness. Curr. Opin. Clin. Nutr. Metab. Care 11: 121-127 (2008).

• Morris T, Stables M, Gilroy DW. New perspectives on aspirin and the endogenous control of acute inflammatory resolution. ScientificWorldJournal 6: 1048-1065 (2006). *

• Navarro-Xavier RA, Newson J, Silveira VL, Farrow SN, Gilroy DW, Bystrom J. A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. Dec 23 [Epub ahead of print] (2009).

• Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. Nov 11 [Epub ahead of print] (2009). *

• Pauwels EK, Kostkiewicz M. Fatty acid facts, part III: cardiovascular disease, or, a fish diet is not fishy. Drug News Perspect. 21: 552-561 (2008).

• Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Brain Res. Rev. 52: 201-243 (2006).

• Poulsen RC, Gotlinger KH, Serhan CN, Kruger MC. Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am. J. Hematol. 83: 437-445 (2008). *

• Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874 (2007). *

• Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr. Opin. Pharmacol. 6: 414-420 (2006).

• Seki H, Tani Y, Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 89: 126-130 (2009).

• Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J. Periodontol. 79: S1520-S1526 (2008). *

• Serhan CN. Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot. Essent. Fatty Acids 79: 157-163 (2008). *

• Serhan CN. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care 8: 115-121 (2005).

• Serhan CN. Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol. Clin. 24: 341-364 (2006).

• Serhan CN. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost. 7 Suppl. 1: 44-48 (2009). *

• Serhan CN. Novel omega-3-derived local mediators in anti-inflammation and resolution. Pharmacol. Ther. 105: 7-21 (2005). *

• Serhan CN. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem. Cell. Biol. 122: 305-321 (2004). *

• Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25: 101-137 (2007). *

• Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 39: 1125-1132 (2004).

• Serhan CN, Chiang N. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics. Rheum. Dis. Clin. North Am. 30: 69-95 (2004).

• Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 153 Suppl. 1: S200-S215 (2008). *

• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361 (2008). *

• Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 73: 155-172 (2004).

• Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, Yang R, Colgan SP, Petasis NA. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176: 1848-1859 (2006). *

• Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037 (2002). *

• Serhan CN, Lu Y, Hong S, Yang R. Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins. Methods Enzymol. 432: 275-317 (2007).

• Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6: 1191-1197 (2005). *

• Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 3: 279-312 (2008). *

• Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206: 15-23 (2009). *

• Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461: 1287-1291 (2009). *

• Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, Colgan SP, Petasis NA, Serhan CN. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties and enzymatic inactivation. J. Biol. Chem. 282: 9323-9334 (2007). *

• Tian H, Lu Y, Sherwood AM, Hongqian D, Hong S. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions. Invest. Ophthalmol. Vis. Sci. 50: 3613-3620 (2009).

• Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, Hong S, Arita M, Serhan CN. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13: 1193-1202 (2006). *

• Vaddadi K. Essential fatty acids and mental illness. Int. Rev. Psychiatry 18: 81-84 (2006).

• van Epps HL. Inflammation control gets fishy. J. Exp. Med. 201: 661 (2005). *

• Vanden Heuvel JP. Cardiovascular disease-related genes and regulation by diet. Curr. Atheroscler. Rep. 11: 448-455 (2009).

• Vassiliou EK, Kesler OM, Tadros JH, Ganea D. Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. J. Immunol. 181: 4534-4544 (2008). *

• Waitzberg DL, Torrinhas RS. Fish oil lipid emulsions and immune response: what clinicians need to know. Nutr. Clin. Pract. 24: 487-499 (2009). *

• Weitzel LR, Mayles WJ, Sandoval PA, Wischmeyer PE. Effects of pharmaconutrients on cellular dysfunction and the microcirculation in critical illness. Curr. Opin. Anaesthesiol. 22: 177-183 (2009).

• Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm. Bowel Dis. 13: 797-799 (2007). *

• Wittwer J, Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 77: 67-77 (2007). *

• Yacoubian S, Serhan CN. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3: 570-579 (2007). *

Number of references = 111

www psc-literature.org